Back to top
more

Cambrex Corporation (CBM)

(Delayed Data from NYSE)

$46.20 USD

46.20
398,613

+2.73 (6.28%)

Updated May 3, 2019 04:02 PM ET

After-Market: $46.20 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce

Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).

    AMAG In-Licenses Global Rights to Orphan Drug Candidate

    AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.

      Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7%

      Vanda Pharmaceuticals (VNDA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

        Verastem Out-Licenses China Rights to Cancer Drug Copiktra

        Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.

          Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate

          Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.

            Cambrex (CBM): Moving Average Crossover Alert

            Cambrex Corporation (CBM) is looking like an interesting pick from a technical perspective

              CBM vs. ILMN: Which Stock Should Value Investors Buy Now?

              CBM vs. ILMN: Which Stock Is the Better Value Option?

                BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%

                BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

                  Should Value Investors Pick Cambrex (CBM) Stock?

                  Cambrex (CBM) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

                    Is Cambrex Corporation (CBM) a Suitable Value Stock?

                    Cambrex Corporation (CBM) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

                      The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

                      The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics

                        Enzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session

                        Enzo Biochem, Inc. (ENZ) shares rose above 13% in the last trading session.

                          Does Cambrex Offer a Great Value Buying Opportunity Right Now?

                          Value investing is easily one of the most popular ways to find great stocks in any market environment.

                            Merck KGaA Expands Distribution Deal with Roche (revised)

                            Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).

                              Momenta (MNTA) to Receive $50M Under CSL Collaboration

                              Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.

                                Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

                                Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group

                                  Genocea Stock Up on Positive Genital Herpes Infections Data

                                  Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections.

                                    Ultragenyx's (RARE) KRN23 Accepted for Review in the EU

                                    Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.

                                      Arena, Eisai Modify Marketing & Supply Agreement for Belviq

                                      Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.

                                        Spark Therapeutics Gets $15M Milestone Payment from Pfizer

                                        Spark Therapeutics (ONCE) received a $15 million milestone payment from partner Pfizer Inc. (PFE) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.

                                          Ocular (OCUL) Reports Positive Phase III Data on Eye Drug

                                          Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.

                                            Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III

                                            Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.

                                              Zacks.com featured expert Kevin Matras highlights: Morgan Stanley, Pennymac Mortgage, Cambrex, DTE Energy and Choice Hotels

                                              Zacks.com featured expert Kevin Matras highlights: Morgan Stanley, Pennymac Mortgage, Cambrex, DTE Energy and Choice Hotels

                                                Top 5 Stocks with Solid Net Profit Margin

                                                Net profit margin reflects a company's ability to convert revenues into profit after deducting all operating and non-operating expenses as well as income tax payable.

                                                  Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

                                                  Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.